AKBA - Akebia Therapeutics, Inc.
| Previous Close | 7.52 |
| Open | 7.27 |
| Bid | 7.00 x 800 |
| Ask | 7.12 x 900 |
| Day's Range | 7.03 - 7.55 |
| 52 Week Range | 2.99 - 10.53 |
| Volume | 1,467,910 |
| Avg. Volume | 1,551,498 |
| Market Cap | 915.499M |
| Beta (5Y Monthly) | 1.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.36 |
| Earnings Date | May 06, 2020 - May 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.04 |
- Thomson Reuters StreetEvents
Edited Transcript of AKBA earnings conference call or presentation 10-Mar-20 1:00pm GMT
Q4 2019 Akebia Therapeutics Inc Earnings Call
- PR Newswire
Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that the Company will present three posters at the upcoming National Kidney Foundation (NKF) 2020 Spring Clinical Meetings Live Virtual Conference. The posters present studies of Akebia's investigational oral HIF-prolyl hydroxylase inhibitor (HIF-PHI), vadadustat, which relates to Nobel Prize-winning science, the hypoxia-inducible factor (HIF) mechanism. The event will take place from March 25 to March 29, 2020. For information about the virtual event, visit: https://www.kidney.org/spring-clinical.
- The National Kidney Foundation Announces Winners of Prestigious Annual AwardsPR Newswire
- RenalytixAI Announces Podium Presentation and Publication on "Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression"PR Newswire
- Business Wire
A Message from Akebia Therapeutics, Inc.’s Chief Executive Officer to Our Patients, Healthcare Providers, and Other Stakeholders During the Rapidly Evolving COVID-19 Pandemic:
At Akebia Therapeutics, the health of our patients and employees is our first priority. As a member of the kidney care community and the much broader biotechnology industry, we are taking proactive precautions to help mitigate the spread of COVID-19 and protect the safety and health of those around us, while adhering to our commitment to ensure that our patients continue to gain access to the therapies that they need.
- Simply Wall St.
Akebia Therapeutics, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates
One of the biggest stories of last week was how Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares plunged 26% in the week...
- Zacks
Akebia Therapeutics (AKBA) Reports Q4 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -35.56% and -27.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced financial results for the fourth quarter and full-year ended December 31, 2019. The Company will host a conference call today, Tuesday, March 10, 2020, at 9:00 a.m. Eastern Time to discuss its fourth quarter and full-year 2019 financial results and recent business highlights.
- ACCESSWIRE
Akebia Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 10, 2020 / Akebia Therapeutics, Inc. (NASDAQ:AKBA) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 at ...
- Zacks
Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted three newly-hired employees options to purchase an aggregate of 15,600 shares of Akebia’s common stock on February 28, 2020, as inducements material to each such employee’s entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
- Simply Wall St.
One Thing To Remember About The Akebia Therapeutics, Inc. (NASDAQ:AKBA) Share Price
Anyone researching Akebia Therapeutics, Inc. (NASDAQ:AKBA) might want to consider the historical volatility of the...
- Zacks
Is the Options Market Predicting a Spike in Akebia Therapeutics (AKBA) Stock?
Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.
- Simply Wall St.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Insiders Increased Their Holdings
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- Simply Wall St.
Analysts Expect Breakeven For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the...
- Insider Monkey
Did Hedge Funds Drop The Ball On Akebia Therapeutics Inc (AKBA) ?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- GuruFocus.com
Seth Klarman Pares Paratek Pharmaceuticals Stake
Renowned guru slims position in struggling biotech that focuses on infectious diseases Continue reading...
- Zacks
Options Traders Expect Huge Moves in Akebia Therapeutics (AKBA) Stock
Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.
- Simply Wall St.
Introducing Akebia Therapeutics (NASDAQ:AKBA), The Stock That Slid 52% In The Last Five Years
This month, we saw the Akebia Therapeutics, Inc. (NASDAQ:AKBA) up an impressive 45%. But that can't change the reality...
- InvestorPlace
5 “Strong Buy” Biotech Stocks With More Than 80% Upside
For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry. Unlike companies that build up their businesses over time at a steadier pace, biotechs rely on just a few studies or trials of their therapies. As a result, favorable outcomes can catapult share prices upwards. An upset, however, can have the opposite effect.This is why it's essential to do your homework before investing in these often difficult-to-gauge stocks. That's where TipRanks.com comes in. Using the platform, I was able to get access to a host of in-depth market data to help me pinpoint the most compelling investment opportunities in the biotech space.To this end, I found not one, not two, but five biotech stocks poised for huge gains in the long-run. I'm not kidding when I say "huge." I'm referring to more than 80% upside potential from the current share price. Not to mention each has received enough bullish recommendations in the last three months to earn a "strong buy" consensus rating.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks to Buy in December Here's the play-by-play. Akebia Therapeutics (AKBA)Source: Shutterstock About 37 million people in the U.S. are affected by chronic kidney disease (CKD). With its commercially available drug, Auryxia, and its other candidate, Vadadustat, in global Phase 3 clinical development, Akebia Therapeutics (NASDAQ:AKBA) wants to provide new treatment options for patients suffering from the disease.While Auryxia sales in its most recent quarter have posed a cause for concern, Piper Jaffray analyst Christopher Raymond is staying onboard. During its third quarter, Auryxia sales came in at $30 million, $2 million less than the five-star analyst estimated. While definitely not the ideal result, the fact of the matter remains that Auryxia has a more important role as a vehicle for Akebia to establish a commercial platform from which to release the "real value driver - Vadadustat."With respect to AKBA's Vadadustat program, both the INNO2VATE and PRO2TECT studies are fully enrolled, meaning that it is on track to report top-line data in Q2 of 2020 and mid-2020, respectively. In two of the drug's Phase 3 pivotal studies conducted by its collaboration partner in Japan, MTPC, data showed that Vadadustat's effect on hemoglobin was sustained in patients with anemia due to CKD, a positive result in terms of efficacy.Bearing this in mind, Raymond maintained his bullish thesis but did reduce the price target from $22 to $15. Despite this drop, this target implies that shares could soar 208% over the next twelve months.Like Raymond, the rest of the Street is betting on this biotech stock. As four "buy" ratings have been assigned in the last three months compared to no "holds" or "sells," the consensus is unanimous: AKBA is a "strong buy." In addition, the $16 average price target indicates 218% upside potential. See the AKBA stock analysis. Aerie Pharmaceuticals (AERI)Source: Shutterstock Aerie Pharmaceuticals (NASDAQ:AERI) is an ophthalmic pharmaceutical company developing innovative treatments for patients with glaucoma and retinal diseases. Despite the major hit shares have taken year-to-date, some analysts argue that AERI is under-appreciated on Wall Street.Part of the problem stems from the company's performance in its most recent quarter. Not only did AERI post an earnings miss, but it also cut its 2019 sales guidance for the second consecutive quarter.However, according to Piper Jaffray's Joseph Catanzaro, there is a positive takeaway from all this. He tells investors that management's outlook for the short-term has become much more "realistic." The analyst adds that he sees little evidence to demonstrate that there has been a reversal in quarterly script trends observed for Rhopressa and Rocklatan, its glaucoma drugs.As a result, Catanzaro kept his "overweight" rating while lowering the price target from $53 to $48. Still, this target conveys his confidence in AERI's ability to climb 159% higher in the next twelve months. * 7 Stocks to Buy With Great Charts All in all, other Wall Street analysts take a similar approach when it comes to AERI. Based on the seven "buys" and no "holds" or "sells" received in the last three months, the bulls have it and the consensus is that the stock is a "strong buy." On top of this, its $42 average price target puts the potential twelve-month gain at 129%. See the AERI stock analysis. Cytokinetics (CYTK)Source: Shutterstock A leader in muscle biology research, Cytokinetics, Inc. (NASDAQ:CYTK) specializes in muscle activators and muscle inhibitors to treat conditions and diseases characterized by muscle weakness, fatigue or diminished muscle function. On the heels of promising new data presented by the company, investor focus has locked in on this biotech.Investors got some good news back in September when CYTK presented data from the Phase 1 study of its CK-274 drug in healthy patients at the annual Heart Failure Society of America (HFSA) meeting. As these results indicated favorable findings in terms of safety and tolerability, CYTK can move forward with its Phase 2 clinical trial to evaluate the drug's effectiveness in patients with obstructive hypertrophic cardiomyopathy (HCM). HCM is an inherited condition that causes part of the heart to get thicker, affecting its ability to pump blood. Given the limited available options in terms of treating heart failure, the drug's implications could fuel massive growth.This outcome prompted a wave of bullish calls to be published, five to be exact. Based on the 100% Street support, the message is clear: CYTK is a "strong buy." Not to mention its $23 average price target suggests there's room for 146% upside from the current share price.One of the analysts singing the biotech's praises is H.C. Wainwright's Joseph Pantginis. Along with his recent "buy" rating, the analyst set a $30 price target, the highest out of the analysts covering the name in the last three months. This means he sees a whopping 216% potential twelve-month gain in store. See the CYTK stock analysis. Novavax (NVAX)Source: Shutterstock Yes, Novavax (NASDAQ:NVAX) is definitely down, but don't count this biotech out just yet. The company, which is best known for producing vaccine candidates, is completely surrounded by bulls. I mean to say that all of the analysts that have covered the stock in the last three months issued a "buy" recommendation, which could be a signal that something positive is around the corner.Oppenheimer analyst Kevin DeGeeter believes that this is in fact the case in spite of the recent headwind it faced. After the company filed an 8-K disclosing that the EMA declined to support use of the conditional marketing authorization pathway for approval of ResVax, its aluminum adjuvanted respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine, in the EU, approval without another clinical trial seems unlikely.However, DeGeeter reminds investors that he is expecting a positive Phase 3 outcome for NanoFlu in the first quarter of 2020. He argues that this could be a potential catalyst for shares. As a result, he remains optimistic about NVAX.In just the past week, H.C. Wainwright's Vernon Bernardino also decided to stay on board. Along with his bullish call, the $17 price target indicates shares could jump a whopping 350% in the next twelve months. * 7 of the Best Internet Stocks to Buy While Bernardino's forecast implies huge upside potential, based on the $23 average price target the Street sees even more. We're talking 512% here. See the NVAX stock analysis. Translate Bio (TBIO)Source: Shutterstock Translate Bio (NASDAQ:TBIO) is pioneering a new approach to treating disease with messenger RNA, with its lead candidate in development for the treatment of cystic fibrosis (CF), a hereditary disease impacting the lungs and digestive system. With the disease affecting 30,000 people in the U.S., there's a huge unmet need.The company has found itself in hot water recently following its decision to terminate its preclinical OTC deficiency program to treat liver disease based on disappointing data."We believe that the success to date in our cystic fibrosis program positions us well to build on our lung delivery platform and maximize the potential of our mRNA technology in additional pulmonary diseases with unmet medical need," CEO Ronald Renaud stated.While this took a toll on shares, Leerink Partners analyst Geoff Porges argues that he views this news as a positive. "It is encouraging to see TBIO commit to this platform and the CF program and is consistent with the groundbreaking potential of its lung LNP delivery system. The decision to abandon the OTCD program was probably relatively easy given the challenges associated with that indication for TBIO and other developers," he noted. To this end, he maintained his bullish call and $20 price target, putting the upside potential at 98%.With 100% Street support, the word on the Street is that TBIO is a "strong buy." Additionally, its $18 average price target suggests a potential twelve-month gain of 81%. See the TBIO stock analysis.TipRanks offers investors the latest insight into eight different sectors by tracking the activity of over 5,000 Wall Street analysts. As of this writing, Maya Sasson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy in December * 7 Unsteady Stocks Investors Should Consider Selling Before 2020 * 7 Entertainment Stocks to Buy to Escape Holiday Blues The post 5 aStrong Buya Biotech Stocks With More Than 80% Upside appeared first on InvestorPlace.
- Benzinga
Large Option Trader Betting On Biotech Stock Akebia Following Insider Buys
On Tuesday morning, Benzinga Pro subscribers received an option alert related to an unusually large Akebia trade. At 8:52 a.m., a trader bought 606 Akebia call options with a $5 strike price expiring on Dec. 20 near the ask price at 45.1 cents. Given the relative complexity of the options market, large options traders are typically considered to be more sophisticated than the average stock trader.
- Thomson Reuters StreetEvents
Edited Transcript of AKBA earnings conference call or presentation 12-Nov-19 2:00pm GMT
Q3 2019 Akebia Therapeutics Inc Earnings Call
- Zacks
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 24.32% and -2.09%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Benzinga
The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...
- Simply Wall St.
Can Akebia Therapeutics (NASDAQ:AKBA) Afford To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- Insider Monkey
Akebia Therapeutics Inc (AKBA) Is Burning These Hedge Funds
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
